Anti-sickling agents
AssigneeG.D. Searle & Co.
InventorsRosalind I. Collinson-Jones, John F. Pardon
Life of this patent
Estimating the term…
Abstract
The use of an anti-sickling agent of one or more of L-lysine-L-phenylalanine, L-lysine-L-tyrosine, L-histidine-L-lysine-L-tyrosine-L-histidine, in particular L-lysine-L-phenylalanine, and salts thereof is disclosed. An anti-sickling composition which comprises one or more of L-lysine-L-phenylalanine, L-lysine-L-tyrosine, L-histidine-L-lysine-L-tyrosine-L-histidine and salts thereof in association with one or more sterile, pharmaceutically-acceptable carriers, diluents and adjuvants is also disclosed.
Claims11
A pharmaceutical composition of use in the treatment of sickle cell disease comprising, as active ingredient, an anti-sickling amount of a compound selected from the group consisting of L-lysine-L-phenylalanine, L-lysine-L-tyrosine and pharmaceutically-acceptable salts thereof in association with a pharmaceutically-acceptable carrier or diluent.
A method for the alleviation of sickle cell disease in a patient suffering therefrom comprising administering to said patient an anti-sickling effective amount of a compound selected from the group consisting of L-lysine-L-phenylalanine, L-lysine-L-tyrosine and pharmaceutically-acceptable salts thereof.
Dependencies are inferred from the claim text.